Bio-Rad Labs Reports Q2 Results

TL;DR

Bio-Rad Q2 sales $678.5M, EPS $1.30. Results are in.

AI Summary

Bio-Rad Laboratories, Inc. announced its financial results for the second quarter ended July 29, 2024. The company reported net sales of $678.5 million and diluted earnings per share of $1.30. This filing also includes information on other events and financial statements.

Why It Matters

This 8-K filing provides investors with Bio-Rad's latest financial performance, including sales and earnings, which are crucial for assessing the company's current health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial results and does not indicate any unusual risks or significant negative events.

Key Numbers

• $678.5M — Net Sales (Second quarter results)
• $1.30 — Diluted EPS (Second quarter results)

Key Players & Entities

• BIO-RAD LABORATORIES, INC. (company) — Registrant
• July 29, 2024 (date) — Date of earliest event reported
• $678.5 million (dollar_amount) — Net sales for the second quarter
• $1.30 (dollar_amount) — Diluted earnings per share for the second quarter

FAQ

Key Financial Figures

• $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
• $500 million — mpany to repurchase up to an additional $500 million of the Company's outstanding common sto
• $578 million — July 31, 2024, a total of approximately $578 million is available for repurchases under the

Filing Documents

• bio-20240729.htm (8-K) — 36KB
• bio-8k812024xex991.htm (EX-99.1) — 413KB
• 0000012208-24-000050.txt ( ) — 638KB
• bio-20240729.xsd (EX-101.SCH) — 3KB
• bio-20240729_def.xml (EX-101.DEF) — 15KB
• bio-20240729_lab.xml (EX-101.LAB) — 27KB
• bio-20240729_pre.xml (EX-101.PRE) — 16KB
• bio-20240729_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

ITEM 2.02 Results of Operations and Financial Condition On August 1, 2024, Bio-Rad Laboratories, Inc. announced its financial results for the quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

ITEM 8.01 Other Events On July 29, 2024, the board of directors of Bio-Rad Laboratories, Inc. (the "Company") authorized increasing the amount available under the Company's 2023 Share Repurchase Program to allow the Company to repurchase up to an additional $500 million of the Company's outstanding common stock. As of July 31, 2024, a total of approximately $578 million is available for repurchases under the Company's 2023 Share Repurchase Program. Repurchases under the 2023 Share Repurchase Program may be made at management's discretion from time to time on the open market, through trading plans in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or through privately negotiated transactions. The 2023 Share Repurchase Program has no time limit and may be suspended for periods or discontinued at any time.

01 Financial Statements and Exhibits

ITEM 9.01 Financial Statements and Exhibits Exhibit Number Description 99.1 Press release of Bio-Rad Laboratories, Inc. dated August 1 , 2024 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-RAD LABORATORIES, INC. Date: August 1, 2024 By: /s/ Roop K. Lakkaraju Roop K. Lakkaraju Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR